CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant-Reference-Cited by-同舟云学术

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Published:2011-05 Issue:5 Volume:19 Page:679-690
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Sakamoto Hiroshi,Tsukaguchi Toshiyuki,Hiroshima Sayuri,Kodama Tatsushi,Kobayashi Takamitsu,Fukami Takaaki A.,Oikawa Nobuhiro,Tsukuda Takuo,Ishii Nobuya,Aoki Yuko

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference49 articles.

1. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications;Bilsland;Neuropsychopharmacology,2008

2. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors;Bossi;Biochemistry,2010

3. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance;Branford;Blood,2002

4. Oncogenic mutations of ALK kinase in neuroblastoma;Chen;Nature,2008

5. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target;Chiarle;Nat. Med.,2005

Cited by 549 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. In-silico QSAR Modeling for Identification of Novel Anticancer Agent as;PHYS CHEM RES;2024

4. AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer;iScience;2024-09

5. Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers;European Journal of Medicinal Chemistry;2024-09